BACKGROUND The process of skin aging is not limited to the face but involves every part of the body, including the hands. A common manifestation of aging of the hands is the loss of volume, which occurs as the skin loses its subcutaneous fat. Injectable dermal fillers have surfaced as a popular method to address such deficiencies.
T he process of aging affects every part of the human body, including the hands. Aging of the hands includes two processes: change in skin texture and loss of volume. The textural changes are mainly related to sun exposure; they involve skin pigmentation, change in skin thickness, and appearance of fine lines, which can be addressed using chemical peels; intense pulsed light; and different types of lasers, including ruby, alexandrite, and fractional photothermolysis.
The loss of volume happens because, as aging occurs, the skin loses its subcutaneous fat and muscles, resulting in thinning skin. In the hands, this condition manifests as loss of fullness and firmness, greater visibility of the blood vessels and tendons, and more visible wrinkles. The overall appearance of the hands is bonier and more fragile, with loss of tone and elasticity.
Volume replacement is treated using different modalities, including autologous fat replacement and injectable dermal fillers, but the fat injection procedure requires harvesting of fat from a donor site. When the fat is transferred, it is still liable to the same wasting effects as the original fat. 1 It also requires special care to harvest so as not to cause irregularities at the donor site.
Dermal fillers are a viable option available to physicians seeking to replace lost volume in patient hands. Injectable permanent fillers include polymethylmethacrylate, polyacrylamide, and silicone. Injectable semipermanent dermal fillers include calcium hydroxylapatite (CaHA), poly-Llactic acid, and autologous fat. 2 This article describes our experiences in working with CaHA to address deficiencies in the aging hand.
Calcium Hydroxylapatite
Approved for cosmetic use by the U.S. Food and Drug Administration in December 2006, CaHA (Radiesse; BioForm Medical, San Mateo, CA) has become a popular filler for soft tissue augmentation. 3 Radiesse consists of CaHA microspheres (25-45 mm) suspended in a gel consisting of water, glycerin, and sodium carboxymethylcellulose, in a 30% microspheres to 70% carrier gel composition. 4 CaHA is the inorganic component of bone and teeth; it is inert and nonantigenic. 5 Advantages of CaHA include ease of application, biocompatibility, incremental volume replacement, and the possibility of successive injections. 6, 7 Although CaHA has a long duration of effect, it is not permanent. Any errors will naturally attenuate over time. Moreover, it produces a smooth and natural-looking result. 1, 8 The product is easy to store and can be kept at room temperature, with a shelflife of 2 years. CaHA is generally not palpable by the 2-week follow-up, making the injected area soft to the touch. 9 The procedure of CaHA injection is similar to the technique used for other deep dermal fillers, it has a smooth consistency, and it can be molded easily to reduce lumpiness. 10 When treating with CaHA for facial volumization, minimal pain, erythema, and bruising are seen. 11, 12 Depending on the areas to be treated, the desired end result with CaHA can often be achieved in a single visit.
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Duration of Effect
With the current formulation, a 1:1 implant to tissue volume defect correction is required, with no need for over-or undercorrection. 4 Duration of correction with CaHA is between 9 and 12 months in most instances. 3 One longevity study showed evidence of CaHA microspheres surrounded by neocollagenesis at 72 weeks. 8 Its use for cosmetic procedures is usually met with high patient satisfaction. In one study of 90 patients, 88% of patients reported good to excellent satisfaction with their results at 6 months.
13
Off-Label Uses of CaHA
Clinical literature suggests that off-label uses of CaHA have proven to be safe and effective. For example, the product is useful for correction of postrhinoplasty contour deficiencies and asymmetries, with patient satisfaction being good to excellent in 11 (85%) of 13 cases. 14 It has been shown to be a safe, simple, cost-effective technique to treat volume deficiency in the anophthalmic orbit. 6 CaHA had a 100% patient satisfaction rate when being used after nipple-areolar reconstruction to maintain or restore projection in selected breastreconstruction patients. 7 The off-label application discussed in this article is a pilot study to evaluate patient satisfaction with CaHA filler on the dorsa of the hands.
Materials and Methods
Patient Population and Enrollment Procedures
Five female subjects aged 60 to 80 were enrolled at Mount Sinai Medical Center in an outpatient setting. All patients had a soft tissue deficiency of the dorsa of the hands that could benefit from treatment according to evaluation done by two of the treating physicians involved in the study. Exclusion criteria included prior soft tissue implant injection at the treatment site, acute or chronic local infections, existing keloidal scarring, current or history of systemic collagen diseases, bleeding disorders, and Raynaud's syndrome or other circulatory disorders.
Informed consent was obtained from each of the subjects after an explanation of the procedure and the follow-up protocol. The explanation clearly included the caveat of this particular use as an off-label application of CaHA. Medical history and current medications were reviewed. Photographs were taken at baseline, immediately after treatment, and at each follow-up visit.
Treatment Protocol
Each CaHA syringe (1.3 mL) was mixed with a syringe containing 2.0 mL of 2% lidocaine. To create a homogenous solution, the lidocaine was first withdrawn in a 3-mL syringe. The syringe was then attached to the CaHA syringe using a Luerlok connector (Baxa, Englewood, NJ). Pushing the plunger of the CaHA syringe back and forth into the 3-mL syringe mixed the lidocaine with the CaHA. Approximately 10 ''passes'' were sufficient for homogeneity without compromising the rheological properties of the product. 15 The CaHA was then withdrawn into the 3-mL syringe and injected using a 25-gauge, 1.5-inch needle.
After being cleaned with alcohol, the skin on the dorsum of each hand was elevated, pinched between two fingers, raised above the vessels and adjacent anatomical structures, and injected with CaHA at a 901 angle to the skin subdermally (Figures 1 and 2 ). An amount of 0.3 to 1.0 mL was injected interdigitally at each of three to five insertion sites until a nodule was raised ( Figure 3) . Each site was then massaged and molded, using the tips of fingers to completely spread the material evenly through the treatment area. The massage was repeated up to three times during the visit to ensure optimal cosmetic end points. 
Digital photographs were taken pre-operatively and immediately after injection, using a standardized photographic setup (Figure 4 ). The physician evaluated subjects for ecchymosis, edema, erythema, extrusion, infection, keloid formation, hypertrophic scarring, hyper-or hypopigmentation, nodules, and other side effects. All treated subjects were seen for follow-up visits in the office after 1, 4, 16, and 24 weeks.
At each of the visits, including follow-up appointments, a physician evaluated subjects, and standardized photographs were taken (Figures 5 and 6) . A questionnaire was also completed at each visit regarding possible side effects. Each subject described her satisfaction level as being very satisfied, moderately satisfied, minimally satisfied, or unsatisfied with the clinical results.
Results
Cosmetic Results
Five patients were enrolled in the study. All attended one injection session during the course of this study; follow-up visits did not require additional injection of CaHA. One syringe of CaHA was injected for each hand, except for one subject who needed two syringes for each hand.
Adverse Effects
Data concerning adverse effects were collected immediately after treatment and at each follow-up visit. No serious complications occurred in any of the subjects involved in the study. No patients complained of pain after treatment, and thus no pain medication was required.
All subjects had mild to moderate erythema, which subsided within a few hours after injection and did not require any treatment. All five subjects also experienced mild to moderate edema after their treatment. In four of the five patients, edema lasted for 2 to 6 days and declined gradually, with no need for intervention. One subject had edema for 3 days immediately after treatment that resolved entirely by the 1-week visit but then reappeared 10 days after injection and persisted for 3 weeks. Treatment with methylprednisolone starting at a dosage of 24 mg and tapered off over a 6-day period led to immediate improvement: more than 70% resolution of edema 2 days into her course of steroids and 100% resolution at day 6, with no rebound edema after completion of the steroid taper. Methylprednisolone was offered only to this patient who developed the recurrence of swelling.
Ecchymosis lasting 7 days from the day of injection and gradually resolving without treatment was observed in one of the subjects. Another subject reported a feeling of warmth and pruritus lasting for approximately 24 hours; diphenhydramine was taken on the day of injection and the following day. The sensation completely resolved on the second day.
One-Week Follow-Up
At the 1-week follow-up, none of the subjects reported any new adverse effects. Four subjects stated that they were very satisfied with the results; the one subject whose edema appeared again 3 days after it had disappeared was minimally satisfied. Her minimal satisfaction was attributed to edema in both hands but slightly more noticeable on the right hand.
Four-Week Follow-Up
At the 4-week follow-up, the same subject was unsatisfied with treatment because of persistent mild edema. She was prescribed methylprednisolone, and upon re-evaluation 3 days after starting the treatment, her edema was much improved, and she was very satisfied with the results.
One subject felt that her left hand was uneven; she was offered the chance to be re-injected on the next visit if she was still feeling the same. Despite this, her satisfaction level at this visit was still moderately satisfied.
One of the patients had a small (2 Â 2 mm), painless papule on the dorsum of her left hand that developed shortly after the injection. She scratched the nodule, and a scab developed that fell off 10 days before her 4-week follow-up visit (which occurred approximately 8 weeks postinjection). She was given 0.1 mL of 10 mg/mL triamcinolone intralesionally at that visit. She was seen for an additional follow-up visit 2 weeks later, at which time she was given an additional 0.1 mL of 10 mg/mL triamcinolone intralesionally. The lesion had completely subsided 1 week after the second injection. She was very satisfied with the results, even at the time when the papule was present. The remaining subjects were very satisfied with the results of their injection. Thus, four of five patients were very satisfied with their results at the 4-week follow-up.
Sixteen-Week Follow-Up
All five patients were very satisfied with the treatment. There were no adverse events.
Twenty-Four-Week Follow-Up
Discussion
Having younger-looking hands is part of having a younger-looking body. Loss of volume is one factor that makes the hands look older.
On a highly mobile area such as the hand, physicians need to remember the importance of selecting filler that is easily kept in place in the original injection area and is unlikely to migrate or extrude. Fibroblasts grow directly on the surface of the CaHA microspheres at the injection and anchor them in place, resulting in injection site tissue consistency similar to that of surrounding tissue. As a result, the material does not react, extrude, or migrate. [16] [17] [18] There has also been no evidence of calcification or ossification. 19 Nevertheless, because there have been limited studies of CaHA in the hands, more time is needed to observe possible adverse effects of this filler for the dorsa of the hands.
When using CaHA, 1:1 correction is the goal, often making the need for additional visits for treatment to reach full correction unnecessary. Our experience was consistent with this single, comprehensive treatment. None of our subjects requested touch-ups; all reached their correction goals with their initial injection. At the 24-week follow-up visit, subjective responses indicated retention of the filling effect of the product, even in the highly mobile hands.
Our study resulted in high patient satisfaction with the clinical appearance of CaHA in the hands, with five of five patients very satisfied at the 24-week follow-up. Previous clinical trials also demonstrated that it is well tolerated and has high patient satisfaction ratings. 20 We found CaHA to be an excellent filler for the aging hand. The appearance of the hands was smooth and natural. The safety of the product, ease of injection, and absence of any serious adverse event make it even more attractive.
In a separate study, Tzikas demonstrated that bruising generally resolves within 2 weeks after using CaHA. 5 Bruising in one of our subjects lasted for 7 days. Although not common, residual swelling after CaHA use can persist for up to 2 months. 5 In our experience, when the swelling lasts for more than 1 week, patient satisfaction tends to decline. We have found treatment with methylprednisolone to be useful to treat swelling, leading to more rapid improvement and greater patient satisfaction.
Many of our subjects encountered short-term side effects, although none were serious according to the patients. All subjects experienced mild to moderate erythema after injection, which subsided over the course of a couple of hours without treatment. We attribute part of this erythema to the massage postinjection. The most common side effect was edema, which occurred in four of five patients. This may be partially due to the 2 mL of lidocaine. Only one patient required treatment, as noted above. Other side effects included ecchymosis in one patient, lasting 7 days from the day of injection and gradually resolving without treatment. Another patient experienced a feeling of warmth and pruritus lasting for approximately 24 hours after injection but resolving the next day with administration of diphenhydramine. Finally, one patient developed a small painless papule on the dorsum of her left hand shortly after injection. With administration of triamcinolone intralesionally, the lesion completely subsided. This small study is valuable in explaining technique and perioperative side effects and management. The combination of CaHA and anesthetic has been associated with less pain than conventional hand injection and characterized by less swelling and bruising. 11 Further studies with a larger sample size should be performed to accumulate more data on the incidence of side effects.
In its currently approved formulation, no local anesthetic is combined with the CaHA. Consequently, a local, regional, or topical anesthetic is required for many patients. 5 We found mixing CaHA with lidocaine to be helpful in terms of time and patient comfort. The mixing meant that no time was required for topical anesthetic preparations to take effect. Premixing the filler also made it much easier to spread naturally with manual massage. In addition, the mixture obviated the need for separate injections for local infiltration. Equally important, pretreatment injections of lidocaine may distort the anatomy and give a false impression of fullness of the hand. All subjects also found the procedure to be completely tolerable, with no need for additional pain relief. Given that the injected area was the dorsum, historically a difficult area to treat without considerable discomfort or without considerable anesthetization to prevent discomfort, makes the procedure even more notable. Finally, although the persistence of other methods of augmentation is sometimes unpredictable, the CaHA lasted nicely to the 24-week follow-up point in all five patients, leading these individuals to be very satisfied with their results.
Conclusion
To the best of our knowledge, this is the first institutional review board-approved study performed to demonstrate the clinical results of CaHA for soft tissue augmentation in the hands. Mixing lidocaine with CaHA was an easy and convenient anesthetic modality for the patients and the physician. The product was found to be safe, easily injectable, and devoid of any serious side effects. Clinical improvement was still seen 24 weeks after the injection. In addition, augmentation was immediate secondary to the deposition of the carrier gel vehicle, with results sustained as neocollagenesis was induced in and around the injection site. Patient satisfaction was high after initial injection and remained so through the follow-up visits. Because of our findings, we predict that CaHa will be a popular application for the hands.
